Illumina Ventures and BNP Paribas Développement have backed a series A round which will help the biotechnology company expand sales and launch a new product.
France-based DNA quantification company Stilla Technologies has raised €16m ($18m) in a series A round led by Illumina Ventures, the corporate venturing arm of genomics technology producer Illumina.
Financial services firm BNP Paribas contributed to the round through its BNP Paribas Développement unit, while Paris Saclay Seed Fund, a university venture fund formed by University of Paris-Saclay, also participated.
Healthcare-focused investment firm Kurma Partners and private equity firms Idinvest Partners and LBO France filled out the round.
Founded in 2013,…
